Skip to main content
. Author manuscript; available in PMC: 2016 May 14.
Published in final edited form as: J Nutr Biochem. 2007 Sep 14;19(6):384–391. doi: 10.1016/j.jnutbio.2007.05.010

Fig. 4. Pharmacologic inhibition of MAT II and SAMe biosynthesis enhances T lymphocyte AICD.

Fig. 4

A, Cycloleucine decreases MAT II activity in dose-dependant manner. Jurkat cells were untreated (0) or treated with indicated concentrations of cycloleucine for 4h. Cell extracts were prepared and MAT II activity was measured as described in the ‘Methods’. Each point represents mean ± SEM of three separate experiments. B, Cycloleucine induces SAMe deficiency in dose-dependant manner. Cell (Jurkat) extracts were prepared from cells that were either untreated (0) or treated with indicated concentrations of cycloleucine for 4h and intracellular SAMe levels were measured. Results are shown as mean ± SEM from three separate experiments.